International Journal of Research in Pharmacy and Allied Science

ISSN: 2583-6544   |  Issues per year: Monthly  |   Indexed In: Google Scholar, CORE, ScienceOpen, Researchgate

ISSN:2583-6544

Abstract View

A Comprehensive Review on Pharmacological Management of Paediatric Demyelinating Disorders

Author(s): Edwin Dias11, 2*2, Riya Fathima V33

Email(s): 1dredwindias@gmail.com

Address:

    1. HOD and Professor, Department of Paediatrics, Srinivas institute of medical science and research centre, Manglore, Karnataka, India 2. Adjunct Professor, Srinivas University, Director of research and publication, India 3. Final year PharmD student, Srinivas college of pharmacy, Valachil, Manglore, Karnataka, India

Published In:   Volume - 4,      Issue - 6,     Year - 2025

DOI: https://doi.org/10.71431/IJRPAS.2025.4606  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Demyelinating diseases of the central nervous system, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM), represent a broad spectrum of neuroinflammatory disorders. These conditions involve immune-mediated destruction of myelin, leading to substantial neurological dysfunction. Pediatric presentations are often more aggressive, yet the long-term prognosis may differ from adult-onset disease. The treatment landscape has transformed dramatically over the past decade, spurred by discoveries into immunological systems and improved medication development. Using data from clinical trials and real-world applications, this study gathers and evaluates new and existing pharmacologic treatments for demyelinating disorders. It addresses pediatric-specific considerations. It also covers acute treatment strategies, disease-modifying therapies (DMTs), immunosuppressive agents, dosing, route of administration, adverse drug reactions, dose adjustments, and necessary lifestyle modifications.

Keywords:

Cite this article:
Edwin Dias, Riya Fathima V. A Comprehensive Review on Pharmacological Management of Paediatric Demyelinating Disorders. IJRPAS, June 2025; 4 (6): 63-68.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4606


1.      Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89.

2.      Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis. Lancet Neurol. 2018 Nov;17(11):978-987.

3.      Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wender P, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2007 Sep 25;69(13):1294-300.

4.      Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: Acute, preventive, and symptomatic. Ther Adv Neurol Disord. 2020 Jan 24;13:1756286419895900.

5.      Huppke P, Huppke B, Ellenberger D, Stark W, Röbl M, Gärtner J. Clinical characterization of pediatric multiple sclerosis after 10 years of follow-up. Neurology. 2021 Apr 27;96(17)\:e2194-e2206.

6.      Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Hartung HP, et al. Secondary progressive multiple sclerosis: New insights. Mult Scler. 2020 Jan;26(1):20-36.

7.      Fujihara K, Greenberg B, Bennett JL. NMOSD: Overview and updates on management. Ann Neurol. 2019 Sep;86(3):407-417.

8.      Greenberg BM, Graves D, Remington G, Harder L, Pardo CA, Bennett JL, et al. Acute treatment of CNS inflammatory demyelinating disease. JAMA Neurol. 2017 Mar 1;74(3):285-293.

9.      Belman AL, Krupp LB, Olsen CS, Gorman MP, Tillema JM, Aaen G, et al. Characteristics of children and adolescents with multiple sclerosis. Pediatr Neurol. 2019 Jan; 94:3-13.

10.  Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.

11.  Waldman AT, Gorman MP, Rensel M, et al. Management of pediatric multiple sclerosis. Curr Treat Options Neurol. 2016;18(3):10.

12.  Steinman L, Brück W, Stadelmann C, Zamvil SS, Hemmer B. The role of BTK in multiple sclerosis: Results from tolebrutinib trials. Lancet Neurol. 2022 Dec;21(12):1012-1024.

13.  Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer-Hulme AJ, et al. Efficacy and safety of ublituximab in relapsing multiple sclerosis. N Engl J Med. 2022 Dec 29;387(26):2411-2421.

Related Images:



Recent Images



Neurological Complications among Pregnant and Post Partum Mothers in a Private Hospital, Yogyakarta, Indonesia
Review on Regulatory Affairs in Pharmaceutical Industry
Cucumber and Mint Soap: Preparation and Evaluation
Topical Delivery in Cosmetics: Enhancing Penetration and Bioavailability
Formulation and Evaluation of Polyherbal Soap
Gelatin: A Widely Used Pharmaceutical Excipient
Therapeutic insights into Saroglitazar: a dual PPAR- α/γ agonist targeting diabetic dyslipidaemia and NAFLD
A Comprehensive Review on Dyslipidemia and Obesity: Pathophysiology, Clinical Implications and Management Approaches
Antidiabetic Herbs and Polyherbal Antidiabetic Formulations –An Overview
Review on Clinical Research and Clinical Trials

Tags


Quick Links


Latest Issues

Popular Articles